RICERCA ITALIANA     

FIRB simili:

• 1 - Sviluppo di metodologie innovative per l'identificazione e la sintesi di nuove molecole a scopo terapeutico: applicazioni nel campo della malattia di Alzheimer
• 2 - Il riconoscimento molecolare nelle interazioni proteina-ligando, proteina-proteina e proteina superficie: sviluppo di approcci sperimentali e computazionali integrati per lo studio di sistemi di interesse farmaceutico
• 3 - Progettazione, sintesi e screening biologico con metodi ad alta resa di librerie combinatoriali di molecole sviluppate a partire da unità strutturali originali, per applicazioni in campo terapeutico e diagnostico
• 4 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 5 - Molecole innovative ad attività antiflogistica ed antitumorale prodotte con metodologie chimiche avanzate
• 6 - Modulazione razionale dell'attività antitumorale di farmaci "classici" tramite intervento selettivo su specifiche cascate regolatorie
• 7 - Sviluppo di Tecnologie Avanzate per lo Studio della Proteomica Differenziale del Segnale (Segnalo-Proteomica)
• 8 - Il sistema di trasduzione del segnale Ca2+: dalle molecole alle funzioni
• 9 - Progettazione, sintesi e valutazione dell'attività antivirale di inibitori indirizzati su bersagli diversi del ciclo di moltiplicazione dei Flaviviridae.
• 10 - Metodologie Innovative di Risonanza Magnetica (RM) in Patologie Tumorali e Cardiovascolari

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA ORGANICA
  • CHIMICA FARMACEUTICA
• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
  • BIOLOGIA MOLECOLARE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Toscana

Bibliografia

[1] Wyvratt MJ, Doherty A. Eds. Next generation therapeutics. Drug discovery in the 21st Century Curr. Opin. Chem. Biol., 2000, vol. 4
[2] Maggio ET, Ramnarayan K. Trends Biotechnol. 2001 19:266-72.
[3] McCawley LJ, Matrisian LM (2001) Curr. Op. Cell Biol. 534-540.
[4] Nagase H, Woessner Jr. JF (1999) J Biol Chem. 274: 21491-21494.
[5] Woessner JF (1991) FASEB J 5:2145–2154
[6] Birkedal-Hansen H (1995) Curr Opin Cell Biol 7:728–735
[7] Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez Otin C (1997) Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 272:4281–4286
[8] Birkedal-Hansen H, Moore WGL, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197–250
[9] Goldring MB (1993) Degradation of articular cartilage in cul-ture: regulatory factors. In: Woessner JF, Howell DS (eds) Joint cartilage degradation. Dekker, New York, pp 281–346
[10] Murphy G, Willenbrock F (1995) Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 248:496–510
[11] Springman EB, Angelton EL, Birkedal-Hansen H, Van Wart H (1990) Multiple modes of activation of latent fibroblast collagenase evidence for the role of a cys-73 active site zinc com-plex in latency and a “cysteine switch” mechanism. for activa-tion. Proc Natl Acad Sci USA 87:364–368
[12] Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K (1999) Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 284:1667–1670
[13] Peress N, Perillo E, Zucker S (1995) Localization of tissue in-hibitor of matrix metalloproteinases in Alzheimer’s disease and normal brain. J Neuropathol Exp Neurol 54:16–22
[14] Stetler-Stevenson WG, Hewitt R, Corcoran M (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7:147–154
[15] Steinman L (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299–302
[16] Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ (1996) Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum
[17] Beckett RP, Whittaker M (1998) Matrix metalloproteinase in-hibitors. Exp Opin Ther Patents 8:259–282; Glaxo Group Ltd. (1998) WO9748685 metalloprotease inhibi-tors. Exp Opin Ther Patents 8:1191–1194; Whittaker M, Brown P (1998) Recent advances in matrix metalloproteinase inhibitor research and development. Curr Opin Drug Discov Dev 1:157–164
[18] Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K (1997) Ro32–3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121: 540–546; Wood ND, Aitken M, Durston S, Harris S, McClelland GR, Sharp S (1998) Cartilage Protective Agent (CPA) Ro 32–3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Agents Actions 49:49–55
[19] Hande K, Wilding G, Riple G, et al (1998) A phase I study of AG3340, a matrix metalloprotease inhibitor, in patients having advanced cancer (abstract). Ann Oncol 9 [Suppl 2]:74
Hirte H, Goel R, Bennett K etal (1998) Phase I study of matrix metalloproteinase inhibitor BAY12–9566 in patients with ad-vanced cancer (abstract). Ann Oncol 9 [Suppl 2]:75
[20] Scozzafava A, Supuran CT (2000) Carbonic anhydrase and matrix metalloproteinase inhibitors. J Med Chem 43(20):3677-3687.
[21] Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
[22] Tomasselli, A.G. and Heinrickson, R.L., Targeting the HIV-protease in AIDS therapy: a current clinical perspective, Biochim. Biophys. Acta 1477, 189-214 (2000)
[23] Richman, D.D., HIV chemotherapy, Nature 410, 995-1001 (2001)
[24] Hertogs, K, Bloor, S., Kemp, S.D., Van den Eynde, C., Alcorn, T.M., Pauwels, R., Van Houtte, M., Staszewski, S., Miller, V. and Larder, B.A., Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples, AIDS 14, 1203-1210 (2000)
[25]Tossi, A., Antcheva, N., Norberdo, S., Benedetti, F., Miertus, S., Bonin, I., Nair, A. C., Del Bello, F., Palù, G., and Romeo D., Aspartic protease inhibitors: an integrated approach for the design and synthesis of diaminodiol based peptidomimetics, Eur J. Biochem. 267:1715-1722 (2000)
[26] Frecer, V., Miertus, S., Tossi, A. and Romeo, D., Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants, Drug Design Discov. 15, 211-231 (1998)
[27] Nair, A.C., Miertus, S., Tossi, A and Romeo, D., A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues, Biochem. Biophys. Res. Commun. 242, 545-551 (1998)
[28] D. Leung, G. Abbenante and D. P. Fairly, Protease inhibitors: current status and future prospects, J. Med. Chem. 43, 305-341 (2000)
[29] C. Abad-Zapatero, R. Goldman, S.W. Muchmore, C. Hutchins, K. Stewart, J. Navaza, C. D. Payne and T. L. Ray, Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents, Protein Science 5, 640-652 (1996)
[30] Staib, P., Kretschman, M., Nichterlein, T., Hof, H. and Morschauser, J., Differential activation of Candida albicans virulence gene family during infection, Proc. Natl. Acad. Sci. USA 97, 6102-6107 (2000)
[31] Cassone, A., De Bernardis, F., Torosantucci,A., Tacconelli, E., Tumbarello, M. and Cauda, R., In vitro and in vivo anticandidal activity of immunodeficiency virus protease inhibitors, J. Infect. Dis. 180, 448-453 (1999)
[32] Gane PJ, Dean PM Recent advances in structure-based rational drug design Curr Opin Struct Biol 2000 10:401-4
[33] Poston et al. Transplantation, 69, 481, 2000
[34] (Martin et al. Transplant proc. 32, 481, 2000
[35] Scheynius, J. Immunol. 156, 1804, 1996
[36] Issekutz AC., Inflamm. Res. 47, S123-S132, 1998
[37] Krueger et al. J. Invest. Dermatol. 115, 333, 2000
[38] Fischer et al. Blood, 77, 249, 1991
[40] Hourmant et al. Transplantation, 62, 1565, 1996).
[41] Morris, G. M., Goodsell, D. S., Halliday, R.S., Huey, R., Hart, W. E., Belew, R. K. and Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function, J. Computational Chemistry, 1998 19: 1639-1662.
[42] Lorber, D. M. Computational drug design, Chemistry & Biology, 1999 6: R227-R228.
[43] Hicks, R.P. Recent advances in NMR: expanding its role in rational drug design, Crr. Med. Chem., 2001 8:627-50
[44] Hajduk PJ, Meadows RP, Fesik SW, NMR-based screening in drug discovery, Q Rev Biophys 1999 32:211-240
[45] Hajduk PJ, Meadows RP, Fesik SW Discovering high-affinity ligands for proteins. Science. 1997 278:497-499
[46] Malmqvist, M. Nature 361, 1993, 186.
[47] Schuck, P. Annu. Rev. Biophys. Biomol. Struct. 26, 1997, 541.
[48] Homola, J., Yee, S.S., Gauglitz, G. Sensors Actuators 54, 1999, 3.
[49] Rich, R.L., Myszka, D.G. J. Mol. Recognit. 14, 2001, 223.
[50] Myszka, D.G. J. Mol. Recognit. 12, 1999, 390.
[51] Rich, R.L., Myszka, D.G. J. Mol. Recognit. 13, 2000, 388.
[52] Salamon, Z., Brown, M.F., Tollin, G. Trends Biochem. Sci. 24, 1999, 213.
[53] Lange, C., Koch, K. Biochemistry 36, 1997, 12019.
[54] Frutos, A.G., Weibel, S.C., Corn, R.M. Anal. Chem. 71, 1999, 3935.
[55] Johnson, L.L., Bornemeier, D.A., Janowicz, J.A., Chen, J., Pavlosky, A.G., Ortwine, D.F. J. Biol. Chem. 274, 1999, 24881.

Parole Chiave

Metalloproteinasi di Matrice (MMP); Docking; NMR screening; Modeling di proteine; Determinazione strutturale di proteine